Capital City Trust Co. FL increased its holdings in Johnson & Johnson (NYSE:JNJ) by 0.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,749 shares of the company’s stock after purchasing an additional 378 shares during the period. Johnson & Johnson accounts for 2.4% of Capital City Trust Co. FL’s holdings, making the stock its 8th biggest holding. Capital City Trust Co. FL’s holdings in Johnson & Johnson were worth $6,236,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Financial Advantage Inc. purchased a new position in Johnson & Johnson in the 3rd quarter worth approximately $28,000. Kessler Investment Group LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $29,000. Eii Capital Management Inc. purchased a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $39,000. Permanens Capital L.P. raised its holdings in shares of Johnson & Johnson by 33.3% during the 3rd quarter. Permanens Capital L.P. now owns 400 shares of the company’s stock worth $52,000 after acquiring an additional 100 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. raised its holdings in shares of Johnson & Johnson by 1.0% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 416,526 shares of the company’s stock worth $58,000 after acquiring an additional 3,994 shares in the last quarter. 67.28% of the stock is currently owned by institutional investors.
Several analysts have recently issued reports on JNJ shares. Barclays raised Johnson & Johnson from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $140.00 to $173.00 in a report on Thursday, December 19th. Sanford C. Bernstein raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price objective on the stock in a report on Friday, October 11th. Credit Suisse Group reaffirmed a “buy” rating and set a $163.00 price objective on shares of Johnson & Johnson in a report on Tuesday, December 31st. Wells Fargo & Co upped their price objective on Johnson & Johnson from $155.00 to $165.00 and gave the stock an “overweight” rating in a report on Thursday, January 9th. Finally, Cantor Fitzgerald started coverage on Johnson & Johnson in a report on Wednesday, November 27th. They set an “overweight” rating and a $160.00 price objective on the stock. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Buy” and a consensus price target of $159.33.
Shares of JNJ opened at $147.01 on Thursday. The stock has a market capitalization of $385.62 billion, a price-to-earnings ratio of 17.97, a price-to-earnings-growth ratio of 2.36 and a beta of 0.71. Johnson & Johnson has a 1 year low of $125.00 and a 1 year high of $147.84. The business’s 50 day simple moving average is $143.07 and its 200-day simple moving average is $134.77. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.26 and a quick ratio of 1.00.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.12. The firm had revenue of $20.73 billion for the quarter, compared to the consensus estimate of $20.14 billion. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS. On average, sell-side analysts expect that Johnson & Johnson will post 8.66 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 25th will be given a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 2.58%. The ex-dividend date of this dividend is Monday, February 24th. Johnson & Johnson’s dividend payout ratio is currently 46.45%.
In other news, EVP Kathryn E. Wengel sold 2,017 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $141.07, for a total transaction of $284,538.19. Following the transaction, the executive vice president now owns 51,736 shares of the company’s stock, valued at approximately $7,298,397.52. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Hubert Joly bought 5,000 shares of the business’s stock in a transaction dated Friday, December 13th. The shares were bought at an average cost of $141.28 per share, for a total transaction of $706,400.00. Following the transaction, the director now owns 5,000 shares in the company, valued at approximately $706,400. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: S&P/ASX 200 Index
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.